Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2023 Earnings Call Transcript

Joe Ciaffoni: Yes, Glenn, this is Joe. I appreciate the question. I would emphasize that there is no change to our thinking. What I can articulate for you is our base case when we did the BDSI acquisition was that there would be a generic entrant in January of 2027. That’s because there was a settlement with Teva. So that’s our base case. I would emphasize they do not have an approved product, and they also relinquished their first filer exclusivity, the remainder – the remaining ANDA filers Alvogen and chemo in their pursuit of in trying to invalidate the BELBUCA patents. There was a favorable rolling in support of BELBUCA that was upheld on appeal. So they are held out of the market with that formulation until 2032. And then I think, as you know recently, chemo, who is pursuing non-infringement received another CRL on their product.

They had communicated that last week. And as I said in response to Greg’s question, we do believe it is very challenging to achieve all doses of BELBUCA without infringing upon the patents, and we’re committed to very strongly defending the IP. The final thing is we have an authorized generic in the event there was a launch if Teva war to launch, and that’s an arrangement with Par Pharmaceuticals. So BELBUCA would have a long tail in that scenario. And the final comment I would make, if you contrast it to what we’re doing with Nucynta, where we’re pulling back on our investment and managing the payer landscape accordingly. We are committed to investing through 2027 with BELBUCA.

Glen Santangelo: Perfect. Thanks for the time.

Joe Ciaffoni: You got it. Thank you.

Operator: Thank you. And there are no further questions at this time. I’ll hand the floor back to Joseph Ciaffoni for closing remarks. Thank you.

Joe Ciaffoni: Thank you, everyone, for joining the call today. We look forward to updating you on our progress and I hope that everybody has a great evening.

Operator: Thank you. This concludes today’s call. All parties may disconnect. Have a good evening.